Genmab — Februar 2021
-
Novartis data show multiple sclerosis patients and nurses prefer Kesimpta
(ofatumumab) Sensoready autoinjector pen https://www.novartis.com/news/media-releases/novartis-data-show-multiple-sclerosis-patients-and-nurses-prefer-kesimpta-ofatumumab-sensoready-autoinjector-pen -
Aktier/tendens: Storm af kursmål kan rykke markedethttps://www.proinvestor.com/investornyt/672177/aktier-tendens-storm-af-kursmal-kan-rykke-markedet
-
Det meste af regnskabet er allerede kendt via J&J. Det er nok nærmere guidance for 2021 som kan rykke kursen. Hvis jeg ikke tager meget fejl, så gik kursen i vejret da de fremlagde guidance for 2019 og sidenhen 2020. Da de har nået begge mål, så vil en aggressiv for 2021 formentlig have en positiv effekt.
-
*gui
dance -
Kesimpta & Arzerra = Novartis, Tepezza = Horizons
-
It will be interesting to see if they only guide Dara, or if they split estimates for the other drugs as well? (doubt it). By calculating Dara royalties on 4.19bn and comparing it to the actual royalties received we should be able to estimate roughly how much JNJ is reducing due to
Halo dispute. The exact % royalty for Tepezza should be released. -
Det er Genmab
-
seneste guideline for 2020 udmeldt 20. august 2020
-
For at være helt præcist 20. august 2020, https://ir.genmab.com/static-files/c8e8f960-4c07-46b7-8643-03c4c58c61ed
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind